|1.||Bartels, M J: 1 article (04/2000)|
|2.||Mar, M: 1 article (04/2000)|
|3.||Brzak, K A: 1 article (04/2000)|
|4.||Zeisel, S H: 1 article (04/2000)|
|5.||Markham, D A: 1 article (04/2000)|
|6.||Stott, W T: 1 article (04/2000)|
|7.||Thornton, C M: 1 article (04/2000)|
06/01/1983 - "The results of this study demonstrate that N-nitrosodiethanolamine is organospecific for the Syrian golden hamster nasal cavity and trachea and that it induces tumors in these sites at doses lower than previously reported."
10/01/1981 - "Weekly subcutaneous injections of N-nitrosodiethanolamine (NDELA) at doses of 1000, 500 and 250 mg/kg body wt for life induced tumors in Syrian hamsters which primarily affected the upper respiratory tract. "
09/01/1986 - "The metabolism of N-nitrosodiethanolamine (NDELA) was studied to assess whether the formation of the beta-oxidated metabolites N-(2-hydroxyethyl)-N-(formylmethyl)nitrosamine (EFMN) and N-(2-hydroxyethyl)-N-(carboxymethyl)nitrosamine (ECMN) is involved in the mechanism of tumor induction in various animal species with different susceptibility to NDELA carcinogenicity. "
01/01/1984 - "Methapyrilene hydrochloride (MPHC), N-nitrosomethylaniline (NMA), N-nitrosomethyl-3-carboxypropylamine (NMCP) and N-nitrosodiethanolamine (NDELA) are reputed to be nonmutagenic carcinogens because they are genetically inactive in Salmonella mutagenesis tests but produce cancer in rats. "
|2.||Chromosome Aberrations (Chromosome Abnormalities)
|4.||N- (2- hydroxyethyl)- N- (formylmethyl)nitrosamine (EFMN)